Related Experiment Videos
Antithrombotic agents: from RGD to peptide mimetics
I Ojima1, S Chakravarty, Q Dong
1Department of Chemistry, State University of New York at Stony Brook 11794-3400, USA.
Bioorganic & Medicinal Chemistry
|April 1, 1995
Summary
Researchers are developing potent platelet aggregation inhibitors, targeting RGD-containing peptides and mimetics, to treat thrombosis in cardiovascular and cerebrovascular diseases by blocking fibrinogen binding to GPIIb/IIIa receptors.
Area of Science:
- Pharmacology
- Biochemistry
- Medicinal Chemistry
Background:
- Thrombosis is a major cause of cardiovascular and cerebrovascular diseases.
- Platelet aggregation plays a critical role in thrombus formation.
- Integrins, particularly GPIIb/IIIa, are key receptors on platelets involved in aggregation.
Purpose of the Study:
- To review recent advances in developing potent inhibitors of platelet aggregation.
- To explore RGD sequence-based peptides and their mimetics as antithrombotic agents.
- To discuss strategies for rational drug design targeting the GPIIb/IIIa receptor.
Main Methods:
- Review of literature on RGD peptides, peptide hybrids, and non-peptide mimetics.
- Analysis of rational design strategies based on pharmacophoric properties of the RGD unit.
- Discussion of receptor specificity for GPIIb/IIIa.
Main Results:
- Development of small RGD-containing peptides and mimetics as effective antithrombotic agents.
- Inhibition of platelet aggregation via competitive blocking of fibrinogen to GPIIb/IIIa.
- Successful application of rational design strategies leading to optimized RGD-based compounds.
Conclusions:
- RGD-based inhibitors represent a promising therapeutic strategy for thrombosis.
- Rational design approaches have facilitated the development of potent and specific GPIIb/IIIa antagonists.
- Further research into specificity is crucial due to the RGD unit's role in other cell surface receptors.